MSLE Satellos Bioscience Inc. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1421642 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $18.43M | $14.36M |
| SG&A expense | $8.03M | $6.04M |
| Operating income | -$26.46M | -$20.40M |
| Pretax income | -$24.70M | -$20.63M |
| Income tax | $172,000 | — |
| Net income | -$24.87M | -$20.63M |
| EPS (basic) | -1.70 | -2.16 |
| EPS (diluted) | -1.70 | -2.16 |
| Weighted avg. shares (diluted) | 14.60M | 9.56M |
| Balance sheet | ||
| Cash & equivalents | $9.80M | $40.07M |
| Short-term investments | $17.91M | $8.47M |
| Current assets | $31.88M | $50.74M |
| PP&E, netmay include right-of-use assets (IFRS) | $5,000 | $4,000 |
| Total assets | $31.89M | $50.75M |
| Current liabilities | $4.11M | $3.58M |
| Total liabilities | $4.11M | $3.58M |
| Shareholders' equity | $27.78M | $47.16M |
| Cash flow statement | ||
| Operating cash flow | -$23.60M | -$18.25M |
| Capital expenditure | $6,000 | $4,000 |
| Free cash flow | -$23.60M | -$18.26M |
| Investing cash flow | -$9.42M | $4.66M |
| Financing cash flow | $2.24M | $37.57M |
| Stock-based compensation | $3.23M | $1.64M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.